Recent events
Recent events tied to this brand in public sources.
Back to profile18 entries
2026
Anthropic launches Model Hardware Standard (MHS) for AI agents to control physical hardware
Anthropic announced the Model Hardware Standard (MHS), a new standard that lets large-model-driven AI agents such as Claude safely and quickly operate physical devices including microscopes, robotic arms, liquid handlers and lasers. MHS was developed from a collaboration with the Howard Hughes Medical Institute (HHMI) Janelia Research Campus and is available as a research preview to a first group of research labs and advanced manufacturers. Hardware and software vendors including AWS, Automata, Danaher, Doosan Robotics, MBF Bioscience, QIAGEN, Tecan, Universal Robots, Hugging Face and Raspberry Pi are adding or testing MHS support.
2022
QIAGEN launches QIAwave kits
QIAGEN announced the launch of three QIAwave nucleic acid extraction kits, which use fewer components and produce less waste than existing kits.
2022
QIAGEN and Atila BioSystems collaborate on prenatal testing for QIAcuity
QIAGEN announced a collaboration with Atila BioSystems to provide non-invasive prenatal testing solutions for QIAGEN’s dPCR franchise and QIAcuity platform.
2022
QIAGEN and Actome enter QIAcuity licensing and co-marketing agreement
QIAGEN announced a co-exclusive licensing and co-marketing agreement with Actome that brings Actome’s PICO-Technology to QIAcuity for digital PCR protein analysis applications. The companies will jointly develop assays; QIAGEN also made an undisclosed investment in Actome as part of the agreement.
2021
QIAGEN and Verogen announce commercialization partnership
QIAGEN announced a commercialization partnership with Verogen. The agreement gives QIAGEN global distribution rights to Verogen's human-identification portfolio, and the companies will also cooperate to commercialize forensic next-generation sequencing workflows.
2021
QIAGEN and Mirati collaborate on KRAS companion diagnostic
QIAGEN announced a global collaboration with Mirati Therapeutics to continue developing a tissue-based KRAS companion diagnostic, initially focused on non-small cell lung cancer.
2021
QIAGEN and DiaSorin launch LIAISON LymeDetect Assay
QIAGEN and DiaSorin announced the launch of the LIAISON LymeDetect Assay for markets accepting the CE mark. The assay is designed to aid detection of early Lyme borreliosis on LIAISON analyzer systems.
2021
QIAGEN launches artus SARS-CoV-2 Prep&Amp UM Kit
QIAGEN announced the launch of its artus SARS-CoV-2 Prep&Amp UM Kit, a COVID-19 testing kit that combines sample preparation and detection. The kit was CE-IVD registered for use in the European Union and other markets; QIAGEN had submitted an application for U.S. Emergency Use Authorization.
2021
QIAGEN announces QIAsphere cloud-based solutions
QIAGEN announced the launch of QIAsphere cloud-based solutions for its QIAstat-Dx syndromic testing platform. The new platform will enable laboratories and QIAstat-Dx users to monitor tests and instrument status remotely.
2021
QIAGEN launches QIAcube Connect MDx
QIAGEN announced the global launch of QIAcube Connect MDx, an automated sample-processing platform for molecular diagnostic laboratories, available in the U.S. and Canada, the European Union and other markets worldwide.
2020
QIAGEN and BioNTech announce companion diagnostic collaboration
QIAGEN announced a strategic collaboration with BioNTech to develop and commercialize a tissue-based companion diagnostic for use with investigational cancer treatment BNT113.
2020
QIAGEN launches NeuMoDx multiplex respiratory test in Europe
QIAGEN launched the NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Test in the European Union and other markets after CE-IVD registration. The test detects and differentiates influenza A and B, RSV, and SARS-CoV-2.
2020
QIAGEN begins US marketing and distribution of QIAreach SARS-CoV-2 Antigen Test
QIAGEN began marketing and distributing the QIAreach SARS-CoV-2 Antigen Test in the United States after applying for FDA emergency use authorization for symptomatic patients.
2020
Thermo Fisher's proposed acquisition of Qiagen fails
Thermo Fisher's proposed €11.3 billion acquisition of Qiagen failed because the shares tendered did not reach the required two-thirds threshold.
2020
Thermo Fisher announces plan to acquire QIAGEN
Thermo Fisher announced that it would acquire QIAGEN for €39 per share in cash, valuing QIAGEN at approximately $11.5 billion. The proposed transaction was expected to be completed in the first half of 2021.
2020
QIAGEN launches therascreen PIK3CA kit in Europe
QIAGEN announced the CE marking and launch in Europe of its therascreen PIK3CA RGQ PCR Kit, a diagnostic assay intended to help identify breast cancer patients with PIK3CA mutations. The source says the assay would be available to European laboratories immediately.
2019
QIAGEN announces QIAseq FastSelect solutions
QIAGEN announced the launch of new QIAseq FastSelect technologies for faster and simpler library preparation in RNA research; the solutions remove unwanted RNA types from samples.
2019
QIAGEN launches enhanced GeneGlobe hub
QIAGEN announced the launch of an enhanced GeneGlobe Design Analysis Hub that combines gene-target exploration, assay configuration, data analysis and follow-up experiment capabilities.